Virology News and Research

Latest Virology News and Research

Discovery Labs reports first-quarter results, updates on Surfaxin and key pipeline programs

Discovery Laboratories, Inc., a biotechnology company developing its novel synthetic surfactant and aerosol technologies for respiratory diseases, today provides an update on Surfaxin® and key pipeline and business initiatives and reports financial results for the first quarter ended March 31, 2010.

28 Apr 2010

International initiative seeks to reduce heterosexual HIV transmission

Los Angeles Biomedical Research Institute has received a $350,000 grant to study the safety of a gel designed to reduce the heterosexual transmission of HIV from the International Partnership for Microbicides, a nonprofit global initiative to develop products to reduce HIV transmission, and the U.S. Agency for International Development, the Institute announced today.

28 Apr 2010

UK MHRA authorizes Presidio Pharmaceuticals to initiate Phase 1 clinical trial of PPI-461 for HCV

Presidio Pharmaceuticals, Inc. announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the initiation of a Phase 1 first-in-human clinical trial of PPI-461, an orally administered NS5A inhibitor for the treatment of hepatitis C virus (HCV). The Phase 1 clinical trial will be conducted in healthy volunteers.

27 Apr 2010

WHO experts to examine polio outbreak in Tajikistan

The WHO said it sent six technical experts to assess a small outbreak of polio in Tajikistan, VOA News reports, adding that WHO "says this is the first importation of polio in the European region since Europe was certified as polio-free in 2002."

27 Apr 2010

Wall Street Journal examines changes to polio eradication strategy

The Wall Street Journal examines upcoming changes to the global strategy to eradicate polio with a focus on the Bill & Melinda Gates Foundation's role in fighting the disease. "[O]rganizations behind the polio fight," which include the WHO, UNICEF, Rotary International and the CDC, "plan to announce a major revamp of their strategy to address shortcomings exposed by" the increasing number of polio outbreaks in "countries believed to have stopped the disease." The plan is expected to be announced next week.

27 Apr 2010

Scientists develop rapid point-of-care diagnostic test to measure CD4 T-cells

Scientists at Australia's Burnet Institute have developed a rapid point-of-care diagnostic test for the measurement of CD4 T-cells, a marker of the immune system for people living with HIV and AIDS.

27 Apr 2010

Santaris Pharma advances into drug development SPC5001 research candidate against PCSK9

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.

26 Apr 2010

Nanoviricides become registered trademark under USPTO

NanoViricides, Inc., announced today that the mark "nanoviricides" has now become a registered trademark under the US Patents and Trademarks Office. The mark was entered into the "principal register" of trademarks at the USPTO on April 20, 2010.

26 Apr 2010

Pevion Biotech to present positive results of PEV4 RSV vaccine candidate at Vaccine Innovation Meeting

Pevion Biotech, the Swiss vaccine company, today announced that it has successfully completed the preclinical safety and efficacy studies of its RSV vaccine candidate PEV4. The vaccine candidate is a modern subunit vaccine candidate against respiratory syncytial virus (RSV), which is based on a recombinant RSV-F protein formulated with Pevion Biotech's proprietary and market-validated virosome technology platform.

26 Apr 2010

Study finds changes in astrocytes key to brain dysfunction

Neuroscience researchers have zeroed in on a novel mechanism that helps control the firing of electrical signals among neurons. By isolating the molecular and electrical events that occur when this control is disrupted, the new research sheds light on epileptic seizures and potentially on other prominent diseases involving poorly regulated brain activity.

26 Apr 2010

1976 "swine flu" vaccine protects against 2009 pandemic H1N1 influenza virus

New evidence shows immunization against "swine flu" in 1976 might provide individuals with some protection against the 2009 pandemic H1N1 influenza virus, according to new research from St. Jude investigators.

24 Apr 2010

Mechanisms pathogenic viruses exploit to evade immune systems of hosts

Viruses have evolved a broad range of strategies that enable them to evade the immune systems of their hosts. A team of researchers led by LMU virologist Professor J-rgen Haas has been studying a novel, recently discovered mechanism that pathogenic viruses exploit for this purpose, and their latest results could point the way to new antiviral therapies. The mechanism is based on the production of short RNA molecules, called microRNAs, by the virus.

24 Apr 2010

Presidio Pharmaceuticals, Numerate conclude collaboration to discover new compounds targeting HCV

Presidio Pharmaceuticals, Inc., and Numerate, Inc., today announced that they have concluded their two-year collaboration to discover new compounds that target hepatitis C virus (HCV).

24 Apr 2010

News outlets examine H1N1's impact on U.S. vaccine development plans, Mexico's handling of outbreak

"A year after the emergence of swine flu [H1N1], U.S. health authorities and laboratories say the pandemic illustrated the need for new vaccine production techniques that are faster and more reliable," Agence France-Presse writes in an article that examines the challenges associated with current vaccine development practices and plans for future development.

24 Apr 2010

Oncolytics Biotech completes Phase I enrollment in Phase I/II trial of REOLYSIN for recurrent malignant gliomas

Oncolytics Biotech Inc. announced today that it has completed Phase I patient enrollment in its Phase I/II clinical trial to investigate the use of REOLYSIN(R) for patients with recurrent malignant gliomas (REO 007). The principal investigator is Dr. James Markert, Division Director of Neurosurgery, and Professor, Neurosurgery and Physiology, the University of Alabama at Birmingham.

23 Apr 2010

GenVec's 2009 revenues down 8%: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring GenVec Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

23 Apr 2010

EpiCept invites stockholders to attend Annual Meeting

With this notice, stockholders of EpiCept Corporation are invited to the Annual Meeting of Stockholders on June 3, 2010, at 10:00 a.m. Eastern time at the Dolce/IBM Palisades Executive Conference Center, 334 Route 9W, Palisades, New York 10964.

23 Apr 2010

Scientists develop new way of modifying viruses to seek out and destroy cancer cells

CANCER RESEARCH UK scientists at the University of Leeds have developed a new way of modifying viruses to seek out and destroy cancer cells, according to research published in Gene Therapy today1 (Friday).

23 Apr 2010

IAVI, Lentigen to design preventive AIDS vaccine

The International AIDS Vaccine Initiative and Lentigen today announced a collaboration to design a preventive AIDS vaccine based on Lentigen's technology. The candidate AIDS vaccine will be devised to safely mimic biological aspects of HIV infection and tested first in pre-clinical studies as part of an initial 18-month agreement.

23 Apr 2010

New gene therapy to restore retinal cone function and day vision

Veterinary ophthalmology researchers from the University of Pennsylvania have used gene therapy to restore retinal cone function and day vision in two canine models of congenital achromatopsia, also called rod monochromacy or total color blindness.

22 Apr 2010

Virology News and Research

Latest Virology News and Research

Discovery Labs reports first-quarter results, updates on Surfaxin and key pipeline programs

International initiative seeks to reduce heterosexual HIV transmission

UK MHRA authorizes Presidio Pharmaceuticals to initiate Phase 1 clinical trial of PPI-461 for HCV

WHO experts to examine polio outbreak in Tajikistan

Wall Street Journal examines changes to polio eradication strategy

Scientists develop rapid point-of-care diagnostic test to measure CD4 T-cells

Santaris Pharma advances into drug development SPC5001 research candidate against PCSK9

Nanoviricides become registered trademark under USPTO

Pevion Biotech to present positive results of PEV4 RSV vaccine candidate at Vaccine Innovation Meeting

Study finds changes in astrocytes key to brain dysfunction

1976 "swine flu" vaccine protects against 2009 pandemic H1N1 influenza virus

Mechanisms pathogenic viruses exploit to evade immune systems of hosts

Presidio Pharmaceuticals, Numerate conclude collaboration to discover new compounds targeting HCV

News outlets examine H1N1's impact on U.S. vaccine development plans, Mexico's handling of outbreak

Oncolytics Biotech completes Phase I enrollment in Phase I/II trial of REOLYSIN for recurrent malignant gliomas

GenVec's 2009 revenues down 8%: MicroStockProfit.com

EpiCept invites stockholders to attend Annual Meeting

Scientists develop new way of modifying viruses to seek out and destroy cancer cells

IAVI, Lentigen to design preventive AIDS vaccine

New gene therapy to restore retinal cone function and day vision

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics